| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 21/12/2023 | 21:32 | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/12/2023 | 00:26 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 01/12/2023 | 17:49 | Edgar (US Regulatory) | Form 8-K - Current report | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 23/10/2023 | 19:56 | Edgar (US Regulatory) | Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 06/10/2023 | 03:01 | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 05/10/2023 | 22:21 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 15/09/2023 | 21:42 | Edgar (US Regulatory) | Form PRE 14A - Other preliminary proxy statements | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 11/09/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 15/08/2023 | 23:53 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 11/08/2023 | 22:06 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 10/08/2023 | 15:29 | Business Wire | Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 31/07/2023 | 15:32 | Business Wire | Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 29/07/2023 | 02:23 | Business Wire | Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 27/07/2023 | 23:20 | Business Wire | Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 13/07/2023 | 23:09 | Business Wire | Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 03/07/2023 | 22:01 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 30/06/2023 | 16:46 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 30/06/2023 | 15:16 | Business Wire | Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 16/06/2023 | 23:23 | Edgar (US Regulatory) | Current Report Filing (8-k) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 16/06/2023 | 23:00 | Edgar (US Regulatory) | Securities Registration (section 12(g)) (8-a12g) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 16/06/2023 | 22:54 | Business Wire | Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 16/06/2023 | 19:52 | Business Wire | Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 07/06/2023 | 22:00 | Business Wire | Navidea Biopharmaceuticals, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 02/06/2023 | 23:54 | Business Wire | Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 01/06/2023 | 23:53 | Business Wire | Navidea Biopharmaceuticals, Inc. Welcomes Jill Bieker Stefanelli, Ph.D. to Board of Directors; Alexander L. Cappello Steps Down | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 01/06/2023 | 12:03 | Edgar (US Regulatory) | Specialized Disclosure Report (sd) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 23/05/2023 | 00:30 | Business Wire | Navidea Biopharmaceuticals, Inc. Investors Purchase $1.1 Million in Preferred Shares at Market | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 11/05/2023 | 23:35 | Business Wire | Navidea Biopharmaceuticals, Inc. Promotes Michael Sherman Blue, M.D., FACEP, to Chief Medical Officer | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 11/05/2023 | 22:57 | Edgar (US Regulatory) | Quarterly Report (10-q) | AMEX:NAVB | Navidea Biopharmaceuticals Inc |
| 08/05/2023 | 22:12 | Business Wire | Navidea Biopharmaceuticals, Inc. Drives Strategy Forward, Shifts Approach for Communications | AMEX:NAVB | Navidea Biopharmaceuticals Inc |